Phase I Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors
Phase of Trial: Phase I
Latest Information Update: 24 May 2017
At a glance
- Drugs Guadecitabine (Primary) ; Cisplatin
- Indications Germ cell and embryonal neoplasms
- Focus Adverse reactions
- 18 May 2017 Planned End Date changed from 1 May 2018 to 31 Dec 2018.
- 18 May 2017 Planned primary completion date changed from 1 May 2017 to 31 Dec 2017.
- 18 May 2017 Status changed from recruiting to suspended.